Effectiveness of an Online Quiz in Promoting Tobacco-Related Knowledge, Attitudes, and Behaviours Among Primary Students
Launched by THE UNIVERSITY OF HONG KONG · Mar 29, 2025
Trial Information
Current as of September 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how an online quiz can help primary school students learn more about the dangers of tobacco and smoking. The main goal is to see if participating in this quiz can improve their knowledge about tobacco, change their attitudes towards smoking, and lower their intention to start smoking. The researchers will compare the quiz answers of students who take part in the online quiz with those who do not, to see if there’s a difference in what they know and how they feel about tobacco.
To be eligible for this study, students must be in Primary 5 or 6 at a local school, be able to read and communicate in Chinese, and have access to a digital device at home to complete the quiz. There are no specific exclusions for this trial. If your child participates, they can expect to engage in a fun and interactive quiz that aims to educate them about tobacco and promote healthier choices. This is an important step in helping young people understand the risks associated with smoking and alternative tobacco products.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Primary 5-6 students from local primary schools
- • Able to read and communicate in Chinese
- • Have a digital device for online access to the quiz game at home
- Exclusion Criteria:
- • None
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, Hong Kong
Patients applied
Trial Officials
Shiu Lun Ryan Au Yeung
Principal Investigator
School of Public Health, The University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported